QCOR News Alert Questcor Pharmaceuticals (QCOR) 93.60 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 93.60 $QCOR

Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 118.55 (-2.23), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), NKTR: 15.31 (-0.29), AGN: 208.47 (-2.67), IPXL: 31.16 (-0.74), ALDR: 25.27 (-1.46), QCOR: 93.60 (+1.52), MRK: 57.72 (-1.62), TSPT: 1.70 (-0.04), RVNC: 17.45 (-0.23), POZN: 9.12 (-0.08)

401(K) Reconstructed - 2014 Q3 Review
Eric Landis - Seeking Alpha - Tue Oct 28, 9:39AM CDT
Background This article is an update to my 401k portfolio , which I have been profiling as it has been transitioned from investments in mutual funds into a dividend growth portfolio. With the change in investing styles, my focus has also changed...
KMI: 39.17 (-0.71), QCOR: 93.60 (+1.52), COH: 35.20 (+0.74), MAT: 30.75 (-0.40), POT: 34.17 (-0.90), LO: 62.55 (-0.63), O: 46.56 (+0.06), AFL: 58.28 (-1.29)

Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 57.72 (-1.62), CGEN: 8.27 (+0.14), TEVA: 55.92 (-0.92), AMPE: 3.66 (+0.15), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82)

Greenberg on the Stock Market: Why Investigations No Longer Matter
at The Street - Mon Oct 20, 10:25AM CDT
I can't remember the last time a company got more than a slap on the wrist.
MNK: 94.72 (-0.36), T: 32.16 (-0.55), QCOR: 93.60 (+1.52), GMCR: 136.28 (-3.41), COCO: 0.09 (unch)

Mallinckrodt shares rise on earnings outlook
AP - Tue Oct 14, 9:07AM CDT
NEW YORK (AP) — Shares of Mallinckrodt PLC rose Tuesday after the health care products maker posted an earnings outlook for next year that beat Wall Street expectations.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52)

Pharmaceutical Industry Confidence Report Q3 2014
M2 - Tue Oct 14, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkxc2t/pharmaceutical) has announced the addition of the "Pharmaceutical Business Confidence Report Q3 2014" report to their offering. Pharmaceutical Business Confidence Report Q3 2014 is a new report that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the pharmaceutical industry. This report also examines executive opinion with regards to the current and future state of the economy and its retrospective effect on the industry. It analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over July - September 2014. In addition, it provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry over July - September 2014. The report features the opinions of pharmaceutical industry respondents about the economic overview covering the following aspects: - State of the economy - Growth prospects and customer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy Key Highlights - Overall, 43% of pharmaceutical respondents state that they are operating in a favorable economic environment, while 37% state that their current economic conditions are stable - The majority of global pharmaceutical industry respondents anticipate positive growth for both the company and industry over July - September 2014 - Industry respondents from Asia-Pacific expect the highest growth in staff headcount and sales volume in July - September 2014 - Improving operational efficiency and customer retention are the most popular priorities for pharmaceutical industry executives operating across all regions Key Topics Covered: - Economic overview - Methodology and sample size - State of the economy - Growth prospects and consumer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy - Appendix Companies Mentioned - Alvogen - DAVA Pharmaceuticals - Dream Pharma Corp. - Endo International - Mallinckrodt - Questcor Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vk...maceutical
QCOR: 93.60 (+1.52)

Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
Business Wire - Mon Oct 06, 7:30AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at the Company's upcoming annual shareholders' meeting, which will be held on November 4.
QCOR: 93.60 (+1.52), BTX: 3.17 (+0.07)

Uveitis Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x3fcg/uveitis_market) has announced the addition of the "Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Alcon, Inc. - Horizon Pharma, Inc. - Merck & Co., Inc. - Bausch & Lomb Incorporated - Alcon Laboratories, Inc. - Pharmacia & Upjohn, Inc. - Pfizer Inc. - Roxane Laboratories, Inc. - Falcon Pharmaceuticals, Ltd. - Organon USA Inc. - Apothecon Inc - Schering-Plough Corporation (Inactive) - Merck Sharp & Dohme Corp. - Sanofi - Questcor Pharmaceuticals, Inc. - Sandoz Inc. - Panray Corporation - Novartis AG - UCB, Inc. - Tiber Laboratories, LLC - Concordia Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/2x...tis_market
AGN: 208.47 (-2.67), QCOR: 93.60 (+1.52), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), HZNP: 12.71 (-0.04), NVS: 93.52 (-0.82)

Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
MNK: 94.72 (-0.36), ACT: 259.00 (-4.00), QCOR: 93.60 (+1.52), UNH: 98.76 (-0.97), BMY: 58.75 (-0.93), CELG: 114.49 (-2.25), CELGZ: 3.51 (-0.03)

Mallinckrodt announces its inclusion in the S&P 500 Index
M2 - Wed Aug 20, 8:09AM CDT
Pharmaceutical company Mallinckrodt (NYSE:MNK) reported on Tuesday that it has now been added to the S&P 500 Index.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52)

The Zacks Analyst Blog Highlights:magicJack VocalTec, RRSat Global Communications Network, Enzymotec, Gulfmark Offshore and Questcor Pharmaceuticals
PR Newswire - Tue Aug 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the magicJack VocalTec Ltd. (Nasdaq:CALL-Free Report), RRSat Global Communications Network Ltd. (Nasdaq:RRST-Free Report), Enzymotec Ltd. (Nasdaq:ENZY-Free Report), Gulfmark Offshore Inc. (NYSE:GLF-Free Report) and Questcor Pharmaceuticals Inc. (Nasdaq:QCOR-Free Report).
QCOR: 93.60 (+1.52), ENZY: 8.00 (+0.21), RRST: 7.87 (+0.02)

Mallinckrodt Now a Component of the S&P 500 Index
Business Wire - Tue Aug 19, 8:20AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it has become a component of the S&P 500 Index. The inclusion comes following the completion of Mallinckrodt's acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company's balance sheet, cash generation and leverage position.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52)

Gulfmark Offshore (GFL) Now Added to S&P SmallCap 600 Index - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 1:00PM CDT
Gulfmark Offshore Inc. (GLF), the provider of offshore marine support and transportation services, will replace Questcor Pharmaceuticals Inc. (QCOR) in the S&P SmallCap 600 after the close of trading on Monday, Aug 18.
QCOR: 93.60 (+1.52), WFT: 10.47 (-0.28), GLF: 19.76 (-1.05), SXL: 42.09 (-1.46)

Mallinckrodt Set to Join the S&P 500; Rowan to Join S&P MidCap 400; GulfMark Offshore to Join S&P SmallCap 600
PR Newswire - Thu Aug 14, 5:07PM CDT
S&P MidCap 400 constituent Mallinckrodt plc (NYSE:MNK) will replace Rowan Companies plc (NYSE:RDC) in the S&P 500, Rowan will replace Mallinckrodt in the S&P MidCap 400, and GulfMark Offshore Inc. (NYSE:GLF) will replace Questcor Pharmaceuticals Inc. (NASD:QCOR) in the S&P SmallCap 600 after the close of trading on Monday, August 18. Mallinckrodt is acquiring Questcor Pharmaceuticals in a deal expected to be completed tonight.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52), GLF: 19.76 (-1.05), MHFI: 88.52 (-2.21), RDC: 19.99 (+0.09)

Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals
PR Newswire - Thu Aug 14, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in fiscal 2015.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52)

Mallinckrodt And Questcor Shareholders Approve Mallinckrodt's Acquisition Of Questcor
PR Newswire - Thu Aug 14, 12:00PM CDT
Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today jointly announced that all proposals necessary for Mallinckrodt's acquisition of Questcor were approved by Mallinckrodt's and Questcor's shareholders at each company's respective shareholder meeting held today.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52)

Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 13.82 (-0.86), QCOR: 93.60 (+1.52), MDCO: 25.39 (-0.19), PFE: 30.95 (-0.70), NKTR: 15.31 (-0.29)

Financial Results, Study Results, and Proposed Merger - Research Reports on Mallinckrodt, Thoratec, WellPoint, Questcor and Regeneron
PR Newswire - Tue Aug 12, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Thoratec Corp. (NASDAQ: THOR), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5653-100free.
MNK: 94.72 (-0.36), QCOR: 93.60 (+1.52), THOR: 31.61 (-0.07), REGN: 416.44 (-7.91), WLP: 128.71 (+0.94)

Questcor Pharmaceuticals Earnings In Retrospect: Down 5.4% in the Last 18 Days (QCOR)
Comtex SmarTrend(R) - Mon Aug 11, 12:16PM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings two weeks ago on July 24th, 2014, analysts, on average, expected the company to report earnings of $1.71 on sales of $261.0 million. The company actually reported EPS of $1.85 on sales of $278.8 million, beating EPS estimates by $0.14 and beating revenue estimates by $17.8 million. Shares of Questcor Pharmaceuticals have slipped from $96.93 to $91.69, representing a loss of 5.4%, since the company reported earnings 18 days ago.
QCOR: 93.60 (+1.52)

Retrophin CEO Under Fire for Twitter Faux Pas
at The Street - Mon Aug 11, 7:00AM CDT
Retropin employees were using alias Twitter accounts -- two of which affected the persona of gangster rappers -- to promote Retrophin and pitch short-sale recommendations of other stocks to followers.
MNK: 94.72 (-0.36), VRX: 138.71 (-0.18), QCOR: 93.60 (+1.52), RTRX: 10.12 (+0.24)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 33

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 81

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 50

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 79

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 65

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 36

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 95

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading

Top 5 Most Recently Viewed Articles

Birkenstock Holding Q1 Earnings Highlights and Insights

Updated Category News Views 174

Birkenstock Holding Q1 Earnings Overview Birkenstock Holding (NYSE: BIRK) recently shared insights from its first quarter earnings report, showcasing the company’s financial performance and strategic advancements. This update reveals not only earnings results but also highlights on how the company is faring in a competitive market. Earnings Results The company's...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 228

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Celebrating Success: Medical Solutions Recognized in Regionals

Updated Category News Views 144

Celebrating Growth and Achievement for Medical Solutions Recognized for three consecutive years as a leader in healthcare workforce solutions Medical Solutions, a prominent name in healthcare workforce solutions, has been honored once again for its exceptional growth trajectory, being listed among the Midwest's fastest-growing companies. This prestigious recognition marks...

Continue Reading
Unlocking the Future: SEALSQ's MS6003 Secure Element Launch

Updated Category News Views 208

Revolutionizing Secure Authentication with MS6003 SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor innovation, has recently announced a significant addition to its product portfolio: the MS6003 secure element chip. This state-of-the-art chip is equipped with a preloaded FIDO2 application, marking a pivotal step towards enhancing passwordless authentication in an era...

Continue Reading
Navigating Income with High-Dividend Utility Stocks Today

Updated Category News Views 114

Staying Afloat with Utility Stocks In challenging market conditions, many investors search for stability. This leads them to utility stocks, particularly those offering attractive dividend yields. Utilities often provide steady cash flows and dividends, making them appealing for income-seeking investors. Dividend Opportunities in Utilities Sector As the market shifts,...

Continue Reading